Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Premium
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • PorteføljeInderes modelportefølje
  • Lær om investering
    • AnalyseskoleLær at læse og forstå aktieanalyse
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsidertransaktionerFølg købs- og salgsaktivitet fra virksomhedsinsidere
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Virtuel analytiker-chatStil spørgsmål og få AI-drevne investeringsindsigter med det samme
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Report from Orexo AB’s extraordinary general meeting, 6 November 2026

ORXSelskabsmeddelelse06.11.2026, 10.25
Download udgivelse

Amendment of the articles of association
The extraordinary general meeting in Orexo AB (publ) (“Orexo”) resolved, in accordance with the board of directors' proposal, to amend the articles of association to enable a new issue of ordinary shares with preferential rights for the shareholders. The resolution comprises alternative amendments to the limits for the share capital and the number of shares.

Approval of the board of directors' resolution on a rights issue
The extraordinary general meeting resolved, in accordance with the board of directors' proposal, to approve the board of directors' resolution of 6 October 2026 on a new issue of ordinary shares with preferential rights for the shareholders. The objective of the rights issue is to strengthen the company's financial position and finance Orexo’s prioritised development activities, payment of the company's share of the expected settlement with the U.S. Department of Justice, DOJ, subject to the execution of a final settlement agreement, and strengthening of the company's working capital. The record date for the right to receive subscription rights is 10 November 2026 and the subscription period runs from 12 November 2026 up to and including 26 November 2026.

Authorisation for the board of directors to resolve on a new issue of ordinary shares to the underwriter
The extraordinary general meeting resolved, in accordance with the board of directors' proposal, to authorise the board of directors to resolve, for the period until the next annual general meeting, on one or several occasions, with deviation from the shareholders' preferential rights, on a new issue of ordinary shares as an underwriting fee to the underwriter that has entered into an underwriting commitment to secure the rights issue. The subscription price shall correspond to the subscription price in the rights issue.

Complete proposals regarding the resolutions by the extraordinary general meeting in accordance with the above are available at Orexo’s website, www.orexo.com.

For further information contact:
Nikolaj Sørensen, President and CEO
ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. Its proprietary AmorphOX® drug delivery technology improves the bioavailability and stability of large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With more than 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of clinical and preclinical programs. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market, and its ADRs trade on the OTCQX market in the United States.

Attachments
Orexo EGM 2026 Bulletin